Radiopharm Theranostics, Ltd

This early-phase study tests a new drug called 177Lu-RAD202 in 30 adults with advanced solid tumors that have a protein called HER2. The drug uses a radioactive particle to seek out and attack cancer cells. The main goals are to check safety, find the right dose, and see how the …

This early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will check for safety and side effect…

This early-phase study tests a new drug called 177Lu-RAD204, which combines a targeting antibody with a radioactive particle to seek out and attack cancer cells. The trial involves 30 adults with advanced solid tumors like lung, breast, or skin cancer that have not responded to o…

This study tests a new radioactive drug (161Tb-RAD402) designed to find and attack prostate cancer cells that no longer respond to standard hormone therapy. About 73 men with castration-resistant prostate cancer will receive the drug to see if it is safe and can shrink tumors or …

This early-phase study is testing a new substance called RAD301 to see how it moves through the body and how much radiation it gives off. It involves 9 people: healthy volunteers and patients with certain cancers like pancreatic, lung, or ovarian cancer. The goal is to measure sa…